Who are Propess,SYNPITAN FORT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dinoprostone vaginal insert, Prostin E2, Administration of Propess.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propess-synpitan-fort.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Propess,SYNPITAN FORT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Propess,SYNPITAN FORT (Propess,SYNPITAN FORT) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin E2 analog. Area: Obstetrics.

phase 3 Prostaglandin E2 analog Prostaglandin E receptor (EP receptor) Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Propess,SYNPITAN FORT (Propess,SYNPITAN FORT) — Erzincan Military Hospital. Propess is a sustained-release dinoprostone (prostaglandin E2) vaginal insert that promotes cervical ripening and uterine contractions to induce labor.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Propess,SYNPITAN FORT TARGET	Propess,SYNPITAN FORT	Erzincan Military Hospital	phase 3	Prostaglandin E2 analog	Prostaglandin E receptor (EP receptor)
Dinoprostone vaginal insert	Dinoprostone vaginal insert	HaEmek Medical Center, Israel	marketed	Prostaglandin E2 analog	Prostaglandin E receptors (EP1, EP3)
Prostin E2	Prostin E2	Ain Shams University	phase 3	Prostaglandin E2 analog	Prostaglandin E receptor (EP receptors)
Administration of Propess	Administration of Propess	Tel-Aviv Sourasky Medical Center	phase 3	Prostaglandin E2 analog	Prostaglandin E receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin E2 analog class)

Ain Shams University · 1 drug in this class
Erzincan Military Hospital · 1 drug in this class
HaEmek Medical Center, Israel · 1 drug in this class
Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propess,SYNPITAN FORT — Competitive Intelligence Brief. https://druglandscape.com/ci/propess-synpitan-fort. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing